Fred Ma - Repro Med Principal Executive Officer
Executive
Dr. Fred Ma is Chief Medical Officer of the Company. He has over 30 years of broad experience based on his neurosurgical practice, with significant emphasis in pharmaceuticals and medical device industries. Prior to joining RMS Medical Products, Dr. Ma was President and Managing Director of Medical Quality International, LLC, a pharmaceutical and medical device development consulting firm, from July 2014 to January 2016. From June 2011 to July 2014, Dr. Ma was the Chief Medical Officer and Board of Director at Innovacyn, Inc. a pharmaceutical company. Dr. Ma has a successful track record in all phases of product research and development culminating in final approvals, clearances, and commercialization. He is prominent within regulatory agencies and a multitude of professional organizations. Dr. Ma has directly designed and supervised numerous product developments, 600 clinical trials, and has obtained many regulatory approvals and clearances in the United States and worldwide since 2016.
| Age | 57 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 845-469-2042 |
| Web | http://www.rmsmedicalproducts.com |
Repro Med Management Efficiency
The company has return on total asset (ROA) of 10.67 % which means that it generated a profit of $10.67 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 0.27 %, meaning that it created $0.27 on every $100 dollars invested by stockholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 444.08 K in liabilities with Debt to Equity (D/E) ratio of 4.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Repro Med Systems has a current ratio of 5.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Repro Med until it has trouble settling it off, either with new capital or with free cash flow. So, Repro Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Repro Med Systems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Repro to invest in growth at high rates of return. When we think about Repro Med's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anne Sonnen | Sun Life Financial | N/A | |
| Suzanne Shepherd | Assurant | N/A | |
| Matt Mansour | QBE Insurance Group | N/A | |
| Jenni Smith | QBE Insurance Group | 52 | |
| Vivienne Bower | QBE Insurance Group | N/A | |
| Michael Joyce | Sun Life Financial | N/A | |
| Peter Smiles | QBE Insurance Group | N/A | |
| Timothy Plant | QBE Insurance Group | 47 | |
| Margaret Murphy | QBE Insurance Group | 43 | |
| Jim Roche | Brp Group | N/A | |
| Adam Brown | United Fire Group | N/A | |
| Peter Grewal | QBE Insurance Group | N/A | |
| Aishling Cullen | Sun Life Financial | N/A | |
| Corbyn Lichon | Brp Group | 31 | |
| Peter Horton | QBE Insurance Group | N/A | |
| Liam Buckley | QBE Insurance Group | N/A | |
| David Lange | United Fire Group | 56 | |
| Carolyn Scobie | QBE Insurance Group | N/A | |
| Claude Sarfo | Assurant | N/A | |
| Tony Jackson | QBE Insurance Group | N/A | |
| Subhashish Sengupta | Assurant | N/A | |
Management Performance
| Return On Equity | 0.27 | |||
| Return On Asset | 10.67 |
Repro Med Systems Leadership Team
Elected by the shareholders, the Repro Med's board of directors comprises two types of representatives: Repro Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repro. The board's role is to monitor Repro Med's management team and ensure that shareholders' interests are well served. Repro Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repro Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen Fisher, CFO and Treasurer | ||
| Robert Allen, Director | ||
| Andrew Sealfon, Co-Founder, Chairman, CEO and President and Head of RandD | ||
| David Anderson, Director | ||
| Donald Pettigrew, President and Chief Commercial Officer | ||
| Manuel Marques, COO | ||
| Fred Ma, Principal Executive Officer | ||
| Mark Pastreich, Director | ||
| Daniel Goldberger, Independent Director | ||
| Cyril Narishkin, Interim COO and Additional Director | ||
| John Fletcher, Independent Director | ||
| Paul Baker, Director | ||
| James Beck, Director | ||
| Brad Sealfon, Marketing Manager and Director | ||
| Eric Bauer, COO | ||
| Arthur Radin, Director | ||
| Joseph Manko, Additional Director |
Repro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Repro Med a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.27 | |||
| Return On Asset | 10.67 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 9.81 % | |||
| Current Valuation | 131.75 M | |||
| Shares Outstanding | 38.38 M | |||
| Shares Owned By Insiders | 44.43 % | |||
| Shares Owned By Institutions | 17.96 % | |||
| Price To Earning | 393.75 X | |||
| Price To Book | 16.13 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Repro OTC Stock
If you are still planning to invest in Repro Med Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Repro Med's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |